Elite Q2 Revenue Up 10% to $40.1M, But Six-Month Gross Margin Falls to 41% and Material Weaknesses Persist
ELTP sits 16% above its 52-week low of $0.211 on light trading volume (0.3× avg).
Summary
Elite's fiscal Q2 revenue rose 10% to $40.1M, but six-month gross margin fell to 41% from 54% and operating income nearly halved; management again reported material weaknesses in internal controls.
Key Events · Earnings and Guidance · ELTP
-
Q2 Revenue Up 10%, Six-Month Down 5%
Three-month revenue rose to $40.1M from $36.3M, but six-month revenue fell to $72.4M from $76.5M on lisdexamfetamine price competition.
-
Gross Margin Collapses to 41%
Six-month gross profit fell 29% to $29.5M from $41.3M as cost of manufacturing rose 22% to $42.9M; operating income nearly halved to $17.5M from $29.9M.
-
Net Income Flattered by Non-Cash Warrant Gain
Six-month net income of $23.2M includes a $9.8M non-cash change in fair value of warrant liabilities driven by a ~33% share-price decline — no cash impact and no new dilution.
-
Material Weaknesses in Internal Controls
Management concluded disclosure controls and internal control over financial reporting were not effective at September 30, 2026, citing insufficient segregation of duties and undocumented controls; remediation is underway.
Analysis · ELTP · Life Sciences
The quarter looks fine on the surface — revenue up 10% to $40.1M and net income of $17.3M — but the six-month picture is deteriorating: revenue down 5% to $72.4M, gross margin down to 41% from 54%, and operating income nearly halved to $17.5M from $29.9M as lisdexamfetamine pricing erodes. The $23.2M of reported net income is flattered by a $9.8M non-cash warrant mark-to-market gain, not operations. Management also concluded disclosure controls and internal control over financial reporting were not effective at September 30, 2026, citing insufficient segregation of duties and undocumented controls — a governance red flag that raises the risk of future restatements. Cash of $34.9M and $102.6M of working capital keep the balance sheet comfortable, but the earnings quality and margin trend are the story.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELTP was trading at $0.25 on OTC in the Life Sciences sector, with a market capitalization of approximately $263.9M. The 52-week trading range was $0.21 to $0.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.